[go: up one dir, main page]

WO2008053992A1 - Procédé efficace pour la détection d'antigène, de virus, de cellules et de micro-organismes - Google Patents

Procédé efficace pour la détection d'antigène, de virus, de cellules et de micro-organismes Download PDF

Info

Publication number
WO2008053992A1
WO2008053992A1 PCT/JP2007/071410 JP2007071410W WO2008053992A1 WO 2008053992 A1 WO2008053992 A1 WO 2008053992A1 JP 2007071410 W JP2007071410 W JP 2007071410W WO 2008053992 A1 WO2008053992 A1 WO 2008053992A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
antibody
binding
antigen
oligonucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/071410
Other languages
English (en)
Japanese (ja)
Inventor
Yuichiro Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNTHERA TECHNOLOGIES Co Ltd
Original Assignee
SYNTHERA TECHNOLOGIES Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SYNTHERA TECHNOLOGIES Co Ltd filed Critical SYNTHERA TECHNOLOGIES Co Ltd
Publication of WO2008053992A1 publication Critical patent/WO2008053992A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis

Definitions

  • the present invention relates to a highly efficient method for detecting an antigen, a method for detecting violets, cells, and microorganisms in a test sample using the detection method, and a kit for detecting the virus and / or microorganism.
  • the present invention relates to a method for detecting hepatitis C virus in a test sample, and a kit for detecting the virus.
  • Viral hepatitis (hepatitis C) caused by hepatitis C virus (HCV) is chronic in 75% of those who develop the disease, and often develops liver cancer with a probability of about 25%. It is known that. At present, it is estimated that approximately 700,000 people exist in Japan as HCV carriers, but early hepatitis C has very few subjective symptoms and it is very difficult to predict the symptoms and progress. In many cases, the patient becomes serious and becomes aware of power and infection. Although the number of new infections is currently decreasing, HCV infection, or hepatitis C, can threaten the lives of infected people and have a major impact on Quality of Life (QOL).
  • QOL Quality of Life
  • hepatitis C can often be healed by treatment with interferon ⁇ , / 3, an antiviral drug ribavirin.
  • interferon ⁇ , / 3 an antiviral drug ribavirin.
  • the correctness of treatment depends largely on the amount of virus possessed by patients with hepatitis C.
  • the therapeutic effect may drop sharply.
  • the amount of HCV is used for predicting the therapeutic effect of interleukin treatment and monitoring the therapeutic effect, and the virus quantification method occupies an important position not only in diagnosis but also in treatment.
  • HCV antibody measurement method HCV-RNA qualitative / quantitative method
  • ⁇ CV core protein quantification method HCV quantification methods
  • the HCV antibody measurement method captures the amount of antibody against the HCV virus produced in the body using recombinant proteins in a region that is known to have high homology and high antigenicity to various HCV virus strains. It is a method that detects and quantifies, and is a useful method because it is relatively simple. Yes (Kuo, G. et al., An assay for circulation g antibodies to a major etiologic virus of human ⁇ _A, ⁇ -B hepatitis., Science, vol.244, p.302-304, 1989). However, in this method, since antibodies are not produced until several weeks after HCV infection, it is extremely difficult to determine the presence or absence of HCV virus immediately after infection. In addition, this method measures the amount of antibody against HCV, not HCV virus, and therefore cannot identify HCV species.
  • the HCV-RNA qualitative / quantitative method is a method that detects and reconstitutes HCV genomic RNA by reverse transcription PCR, etc. (Okamoto, Tsuji, et al., Detection of hepatitis C virus RNA by a two -stage polymerase chain reaction with two pairs of primers deduced from the 5'_non cording region., Tpn. J. Exp. Med., vol.60, p.215-222, 1990), very sensitive, Even the amount of virus at the early stage of infection can be detected.
  • the HCV core protein quantification method is a method for detecting and quantifying HCV by various immunoassays using antibodies to the HCV core protein.
  • ELISA Enzyme-Linked Immunosorbent Assay: enzyme immunity , / Law; ⁇ method Noya is known to be based on immunoassay methods such as IRMA (Immunoradiometric Assay), written by Eiji Tanaka et al. "Evaluation of usefulness", New drugs and clinical medicine, published by National Institute of Medical Information, vol.50 (8), p.109-119, 2001; written by Eiji Tanaka et al., "Evaluation of oso HCV antigen IRMA test, ...
  • IRMA Immunoradiometric Assay
  • the HCV core protein quantification method has a correlation with other test methods that are inexpensive and sensitive, and can be operated. Has many advantages, such as being relatively easy, and has been put to practical use as various test reagents and clinical test kits. Therefore, even with this method, it is difficult to detect a trace level of HCV that can sufficiently exert the therapeutic effect of interleukin administration. When new HCV infection is confirmed, treatment with interleukin administration has already been performed. There are some cases where the amount of virus is impossible! [0006] From the above, there is a strong demand for the development of a method for detecting HCV that is simple, low-cost, and more sensitive.
  • the problem to be solved by the present invention is to provide a method that is simple and low-cost, and that can easily detect trace levels of antigens, viruses, cells, and microorganisms that were not possible to detect in the past. There is to do.
  • the present invention is as follows.
  • a method for detecting an antigen comprising:
  • a method for detecting viruses and / or microorganisms is a method for detecting viruses and / or microorganisms.
  • the detection method of the present invention can further include, for example, a step of quantifying viruses and / or microorganisms in the test sample using the detection result of the amplification product as an index.
  • examples of the amplification method include a real-time PCR method
  • examples of the binding substance include an antibody.
  • examples of the virus include hepatitis C virus.
  • a secondary antibody against the virus and / or microorganism A secondary antibody against the virus and / or microorganism
  • a binding substance labeled with an oligonucleic acid strand A binding substance labeled with an oligonucleic acid strand
  • a kit for detecting viruses and / or microorganisms A kit for detecting viruses and / or microorganisms.
  • examples of the virus include hepatitis C virus.
  • FIG. 1 is a diagram showing a detection result (a) of HCV core protein by the detection method of the present invention, and an approximate curve (b) created based on the least square approximation method in a detectable range.
  • FIG. 2 is a diagram showing the results of detection of HCV core protein by ELISA.
  • FIG. 3 is a diagram showing a comparison between the detection result of the HCV core protein by the detection method of the present invention (FIG. 1 (a)) and the detection result of the HCV core protein by the ELISA method (FIG. 2).
  • the detection target in the detection method of the present invention is a force that is an antigen.
  • the type thereof is not limited and may be any protein, sugar, glycoprotein, and the like.
  • the antigen is recognized by an antibody, its location and state are not limited, and it is an antigen present on the cell surface or in the cell, whether it is a purified antigen or a virus antigen. Even if the virus or cells remain alive, they may be fixed, destroyed, extracted or purified.
  • viruses include hepatitis C virus, hepatitis B virus, human immunodeficiency virus, cells include microorganisms such as Escherichia coli, tetanus, Staphylococcus aureus and chlamydia, cultured cells such as plants and animals, animals and Examples include cells derived from plant tissues.
  • hepatitis C virus is preferable.
  • a purified antigen for example, it may be free in a liquid or immobilized on a support.
  • the antigen when the antigen is solid-phased, for example, even if the antigen is directly bound to a support such as a coated plastic dish, the antibody of the antigen adheres to the support and the antigen is attached to the antibody. It may be indirectly bonded to the support, such as adhering.
  • the support is not particularly limited.
  • the method for detecting an antigen of the present invention includes the following steps (i) to (iv).
  • binding substance binding step (ii) a step of binding a binding substance that binds to the first antibody labeled with an oligonucleic acid chain to the first antibody that binds to an antigen (binding substance binding step);
  • the detection method of the present invention may include other steps in addition to the above steps.
  • the antigen is quantified using the detection result of the amplification product as an index.
  • the process quantitative process is preferred.
  • the first antibody used in this step is not particularly limited as long as it can bind to the target antigen, such as the type of antibody (eg, IgG, IgM, etc.) and the origin of animal species (eg, mouse, rat, rabbit, etc.). Nare ,.
  • the type of antibody eg, IgG, IgM, etc.
  • the origin of animal species eg, mouse, rat, rabbit, etc.
  • a test sample containing viruses or cells is subjected to a disruption process, an extraction process, a purification process, etc. according to a conventional method, and the first antibody is administered to the obtained sample to bind to the antigen.
  • the binding substance used in this step means a substance that is labeled with an oligonucleic acid chain and that can specifically bind to the first antibody bound to the antigen.
  • the binding mode between the first antibody and the binding substance may be a mode in which they are directly bound to each other, or through another substance bound to the first antibody (that is, the binding substance is the relevant substance).
  • the other substances are not limited, but preferred examples include various proteins (for example, enzyme proteins such as HRP) used as a labeling substance for the first antibody used in the immunoassay.
  • the binding substance is any substance as long as it has a configuration in which any substance capable of binding directly or indirectly specifically with the first antibody is labeled with an oligonucleic acid chain.
  • an antibody labeled with an oligonucleic acid chain (second antibody) is preferable.
  • the first antibody or the other substance bound to the first antibody becomes an antigen for the second antibody, and examples of the second antibody include an anti-Ig antibody and an anti-HRP antibody.
  • nucleic acid amplification methods include, for example, a nucleic acid amplification method (for example, PCR method) in which a reaction is carried out under a plurality of temperature controlled conditions using a thermal cycler, etc. Law) There is no limit.
  • the amplification region by the nucleic acid amplification method may be a part or all of the oligonucleic acid chain.
  • the region that binds to the PCR primer is a region that includes two regions that serve as a basis for designing a primer set composed of an F primer and an R primer, and can be amplified using this primer set. It means a region, and the specific nucleic acid sequence is not limited.
  • the PCR method is preferably a real-time PCR method from the viewpoint of ease of detection and quantification described later.
  • the oligonucleic acid chain having a binding region with a TaqMan probe is used.
  • the region binding to the primer for LAMP method is FIP, BIP, F3 primer, B3 primer
  • the specific nucleic acid sequence is not limited.
  • the region that binds to the ICAN primer is a region that includes two regions that are the basis for designing a primer set composed of two chimeric primers (one of the F and R primers). It means a region that can be amplified using, and the specific nucleic acid sequence is not limited.
  • the oligonucleic acid chain to be labeled is, for example, one having a region cleavable by a restriction enzyme, one having a region cleavable by light irradiation, or one having a region cleavable by active oxygen. May be.
  • the oligonucleic acid chain containing the amplification region can be separated and isolated from the complex with the binding substance to form a cage, and a more efficient amplification reaction can be performed.
  • the oligonucleic acid chain is an oligonucleotide chain (oligo DNA chain, oligo RNA chain (especially oligo DNA chain)), oligopeptide nucleic acid chain (oligo PNA chain), or a mixture thereof.
  • Preferred is a strand, and more preferred is an oligonucleotide chain.
  • oligonucleic acid chains include those containing oligopeptide chains in part. When the oligopeptide chain is contained at one end of the oligonucleic acid chain, for example, in order to facilitate the labeling of the binding substance, or to cleave the oligopeptide chain later when it is separated from the binding substance, Peptide chains can be used.
  • Oligonucleic acid strands are natural products. However, it is usually preferable to be a synthetic product.
  • the length of the oligonucleic acid chain used as a label is not particularly limited. For example, it is preferably 100-5, OOOmer, more preferably 100-1,000 mer, and still more preferably 100-50 Omer. When the length of the oligonucleic acid chain satisfies the above range, it is easy to conjugate (label) to the binding substance, stabilize the state after complexing, improve detection sensitivity, and shorten the detection time. Can do.
  • the binding substance labeled with the oligonucleic acid chain can be prepared, for example, by covalently binding one end of the oligonucleic acid chain to the binding substance body.
  • one or two or more thiol groups, amino groups (substituents), biotin (or avidin), etc. are introduced into the oligonucleic acid chain by chemical or enzymatic treatment (preferably chemical treatment). May be. This facilitates complexation with a binding substance, further stabilizes the state after complexation, improves the yield, and increases the detection sensitivity and detection effect.
  • the method of labeling the oligonucleic acid chain on the binding substance is as follows: (a) Fixing the oligonucleic acid chain with an amino group or thiol group at the 5 'end to the binding substance using a divalent cross-linking agent (See E. Hendrickson et al., Nucl. Acids Res., Vol.23 (3), p.52 2-529 (1995)) and (b) Preferred is a method of immobilizing the oligonucleic acid chain to the binding substance via avidin by mixing the binding substance and the oligonucleic acid chain and adding avidin.
  • a divalent cross-linking agent See E. Hendrickson et al., Nucl. Acids Res., Vol.23 (3), p.52 2-529 (1995)
  • Preferred is a method of immobilizing the oligonucleic acid chain to the binding substance via avidin by mixing the binding substance and the oligonucleic acid chain and adding avidin.
  • an oligonucleic acid chain that becomes a labeling moiety can be complexed with a binding substance via at least a part of the adapter.
  • the structural stability after complexation can be further enhanced, resulting in a higher yield and higher detection sensitivity and detection effect.
  • the adapter portion for example, any protein selected from protein G, protein A, and protein L may be used, and it may be a fusion protein with at least two proteins selected from protein G, protein A, and protein. It may be a fusion protein of at least one protein selected from protein G, protein A and protein L and another protein, or any combination thereof.
  • This adapter protein is preferable because it can be easily and stably bound to the antibody, particularly when the binding substance is an antibody molecule.
  • proteins other than protein G, protein A, and protein L include anti-IgG antibodies.
  • the method of complexing the oligonucleic acid chain and the binding substance via the adapter part is, for example, (0 First, the oligonucleic acid chain is bound to the adapter part, and (ii) The adapter part is then bound to the binding substance. Specifically, in (i), the adapter part is avidin-modified, the oligonucleic acid chain is biotinized, and the both are mixed to bind the oligonucleic acid chain to the adapter part.
  • the adapter part and the oligonucleic acid chain are vitinized in advance / !, and the adapter part and the oligonucleic acid chain are mixed and added with avidin to convert the oligonucleic acid chain into the adapter part via avidin.
  • the avidin modification of the adapter part starts with the linker compound as the adapter part. After the binding reaction, avidin may be bound to the compound.
  • the adapter part used here is protein A, G or L, etc.
  • as a linker compound for example, “Sulfosuccinimidyl 4- (N- maleimidomethyl) cyclohexane-l-carboxylate (Sulfo_SMCC) ”etc.
  • the key obtained in (i) can be used.
  • a complex can be obtained by mixing the conjugate part of the doveter / label part and the binding substance, and if the adapter part and the binding substance do not have binding reactivity originally, for example, both of them are biotin.
  • the oligonucleic acid chain and the binding substance can be complexed using a method similar to the method that can be used in (i), such as mixing in the presence of avidin.
  • a reaction in which the first antibody bound to the antigen or another substance bound to the first antibody is brought into contact with the above-described binding substance (including a solution state), that is,
  • the reaction for binding the first antibody or other substance to the binding substance is not limited in its method and conditions, and can be set as appropriate.
  • the reaction is preferably performed by stirring at room temperature for 30 to 60 minutes. Before the contact, it is desirable to perform a blocking treatment with a known blocking solution in advance. After the above reaction, the substance is bound to the first antibody or other substance by washing with a known washing solution such as PBS. Remove unnecessary components other than.
  • the oligonucleic acid chain in the binding substance after the binding step is amplified by the various amplification methods described above (for example, PCR method, LAMP method, ICAN method). Specifically, oligonucleic acid is obtained by mixing a predetermined primer set, DNA synthase, substrate, etc. (including solution state) in the system after the binding step and reacting under a predetermined temperature control condition. Amplifies a given region of the chain. Further, as the nucleic acid amplification method, it is preferable to use a real-time PCR method (for example, intercalator method, TaqMan method, cyclin probe method) so that amplification products can be easily detected in the detection step described later.
  • the reaction solution composition and reaction conditions (temperature, time, etc.) in the nucleic acid amplification method can be appropriately set by conventional methods.
  • an appropriate restriction enzyme is added to the system obtained in the binding step in advance.
  • an oligonucleic acid chain can be isolated and amplified as a cage. If the oligonucleic acid chain to be labeled has a region that can be cleaved by light irradiation, the oligonucleic acid chain is isolated in advance by irradiation with light of a predetermined wavelength, and this is amplified as a cage. That power S.
  • oligonucleic acid chain to be labeled has a region that can be cleaved by active oxygen
  • a reagent that produces and releases free radicals such as HRP (horseradish peroxidase) and Fe complexes is added in advance to activate.
  • HRP horseradish peroxidase
  • Fe complexes Fe complexes
  • detecting the amplification product obtained in the amplification step By detecting the amplification product obtained in the amplification step, the presence or absence of the antigen in the test sample can be confirmed.
  • Detection of the amplification product can be performed by appropriately selecting from known detection means used in various nucleic acid amplification methods. For example, it can be easily performed by various electrophoresis methods, turbidity measurement, and visual observation, and when a real-time PCR method is used, it can be performed by detecting a predetermined fluorescence wavelength with a spectrofluorometer.
  • the antigen of can also be quantified.
  • the quantification can be performed by appropriately selecting from known quantification methods used in combination with various nucleic acid amplification methods. Specifically, for example, measurement of band concentration after electrophoresis using a densitometer, turbidity measurement (monitoring) of an amplification product using an absorptiometer or spectrophotometer, fluorescence intensity measurement (monitoring) using a spectrofluorometer, etc. Using the measurement results obtained by the above method as an index, a method of quantifying by comparison conversion with the measurement results (calibration curve, etc.) of controls prepared in advance can be mentioned.
  • the method for detecting hepatitis C virus of the present invention includes the following steps (i) to (v).
  • binding substance binding step A step of binding a binding substance (for example, a tertiary antibody (corresponding to the second antibody)) labeled with an oligonucleic acid chain to a secondary antibody bound to the virus (binding substance binding step)
  • a binding substance for example, a tertiary antibody (corresponding to the second antibody)
  • the detection method of the present invention may include other steps in addition to the above steps, and is not limited to, for example, (vi) in the test sample using the detection result of the amplification product as an index. Of quantifying hepatitis C virus (quantitative process), (vii) comparing the amount of virus quantified with other factors (for example, severity of inflammation caused by cytodynamic force-in and liver condition as clinical findings) The process of diagnosing the current medical condition is preferred. Below, the detail about each said process is demonstrated.
  • the test sample containing hepatitis C virus is usually a component collected from a living body (for example, blood, serum, plasma, saliva, urine, tissue fragment), but it is not limited and collected.
  • a biological component may be appropriately subjected to a known treatment in the field of various detection methods. Since the detection method of the present invention is extremely sensitive, hepatitis C, which is included in a trace amount of saliva and urine, which are not normally used as test samples in the detection of hepatitis C virus, among the above biological components. Viruses can be easily detected. Thus, by detecting the hepatitis c virus using the patient's blood, plasma, saliva and urine as the test sample, the presence or absence of hepatitis C virus infection is non-invasively detected in the patient. That's the power S.
  • the amount of hepatitis C virus in the test sample is not limited. For example, even if the amount of virus per mL of the test sample is less than ng in terms of weight, It can be clearly detected, and may be below the pg order, and may be below the fg order. In the previous report, it was reported that all patients treated with interferon showed complete efficacy when the hepatitis C virus level in hepatitis C patients was 330 fg / mL (15 fmol / L) or less. (J. New Rem. & Clin., Vol. 50, 8, p.865-875, 2001).
  • the detection method of the present invention is extremely sensitive, it can be sufficiently detected even if the amount of hepatitis C virus in the test sample is not more than the above virus amount (330 fg / mL), and not more than 20 fg / mL. Even the amount of virus can be detected.
  • the primary antibody used in this step is not particularly limited as long as it is an antibody that can specifically bind to hepatitis C virus.
  • antibodies against HCV envelope, HCV core protein and the like are preferable.
  • the primary antibody used in this step is preferably a solid phase immobilized antibody.
  • the primary antibody is preferably fixed to an arbitrary support.
  • a solid-phased primary antibody substances other than hepatitis C virus in the test sample can be efficiently excluded, and the selectivity of the virus can be increased. Reduce power by S.
  • As a support for immobilizing the primary antibody an antibody molecule can be immobilized, and the test sample, a secondary antibody and a binding substance (including a solution state) described later are added to the antibody molecule.
  • a support insoluble materials and shapes are usually used.
  • known supports that can be used in the assembly system by antigen-antibody reaction are preferred, such as multi-plastic wellore plates, plastic beads, latex beads, magnetic dejugate beads, plastic tubes, nylon membranes, and A nitrocellulose membrane is preferred.
  • Immobilization (immobilization) of the primary antibody to the support can be performed by a known method in immunoassay, and is not limited. In addition, a commercially available support on which a primary antibody is immobilized in advance may be used.
  • the binding reaction (antigen antibody reaction) between the hepatitis C virus in the test sample and the primary antibody immobilized on the support is performed by bringing the test sample into contact with the support.
  • Various reaction conditions such as reaction temperature and reaction time can be appropriately set according to conventional methods of immunoassay.
  • This step is a step of binding the secondary antibody to the hepatitis C virus bound to the primary antibody.
  • the secondary antibody is preferably an antibody that can specifically bind to the hepatitis C virus and has a different epitope than the primary antibody, but is not limited thereto.
  • the secondary antibody for example, antibodies against core protein, envelope protein El, envelope protein E2 and the like are preferable, and antibodies against core protein are preferable.
  • the binding reaction (antigen-antibody reaction) between hepatitis C virus and the secondary antibody is carried out by bringing the secondary antibody solution into contact with the support.
  • Various reaction conditions such as reaction temperature and reaction time can be appropriately set according to conventional methods of immunoassay.
  • unnecessary components other than the secondary antibody bound to hepatitis C virus are removed by washing with a known washing solution such as PBS.
  • an antibody that has been previously labeled with an oligonucleic acid chain described later that is, an oligonucleic acid chain labeled with a binding substance described later
  • the joining process described later can be simplified and more rapid detection is possible.
  • the binding substance binding step, the amplification step, and the detection step may be performed in the same manner as in the case of antigen detection.
  • hepatitis C virus in the test sample can be quantified by using the result obtained in the detection step as an index.
  • the quantification method may be performed in the same manner as the antigen detection.
  • the kit for detecting hepatitis c virus of the present invention comprises: (0) a support on which a primary antibody against hepatitis c virus is immobilized, (ii) a secondary antibody against hepatitis C virus,
  • the kit of the present invention can be used effectively for carrying out the above-described detection method of the present invention, and is extremely useful.
  • the kit of the present invention may contain other components in addition to the components (i) to (iv) listed above.
  • Other components include, for example, dNTP, DNA polymerase, probes (TaqMan probe, cyclin probe, etc.), fluorescent reagents (DNA intercalators such as SYBR Green I, etc.), RNase H, restriction enzymes, various buffers, sterile water , Various reaction vessels (Eppendorf tubes, etc.), blocking agents (serum components such as Bovine Serum Albumin (BSA), Skim milk, Goat serum), and preservatives such as detergents, surfactants, sodium azide, etc.
  • BSA Bovine Serum Albumin
  • Skim milk Skim milk
  • Goat serum Goat serum
  • preservatives such as detergents, surfactants, sodium azide, etc.
  • thermo cycler In addition to the experimental operation manual (instructions), etc., if necessary, a thermal cycler, a thermostatic chamber (any liquid, gas or solid medium), turbidity measurement device (minute Control or measurement equipment such as a photometer, etc.) and a spectrofluorometer.
  • HCV antigen ELISA test manufactured by soso 'clinical' Diagnostic
  • standard diluent were used to prepare a dilution series of HCV recombinant antigen solution.
  • an antigen standard solution 72 pg / mL was added to a standard dilution solution (208 mL) and diluted by a factor of 3.6 to prepare a 20 pg / mL antigen standard solution.
  • this 20 pg / mL antigen standard solution is diluted 5-fold with a standard dilution solution to prepare a 4 pg / mL antigen standard solution, and then the 5-fold dilution operation is repeated four times in the same manner to obtain 0.0064 pg
  • a dilution series up to an antigen standard solution of / mL (6.4 fg / mL) was prepared.
  • a cleaning solution (attached to the kit; 10-fold diluted with MilliQ was used) was added ⁇ OL / well, allowed to stand for 20 seconds, and then the cleaning solution was removed with an aspirator. The same washing operation was repeated 5 more times (6 times in total).
  • Binding step sensitization of oligonucleic acid chain-labeled antibody
  • an anti-HRP antibody labeled with a predetermined oligonucleotide is prepared by the following procedure.
  • a 550-mer oligonucleotide was prepared by PCR using pcDNA3.1 (manufactured by In vitrogen) with Pinl inserted as a truncated DNA and using the following primers (5_MUSTagBio, 3-MUsag515).
  • 5-MUSTagBio had biotin bound to the 3 ′ end and was used as the 5 ′ primer.
  • 3_MUSTag515 was used as the 3 ′ primer.
  • reaction solution composition ⁇ Reaction solution composition>
  • the amplification product after each PCR was purified to a single oligonucleotide by subjecting the supernatant obtained by centrifugation after PCR to filter purification using a MinElute PCR Purification spin column (Qiagen).
  • anti-HRP antibodies Usagi-derived anti-HRP monoclonal antibodies
  • an anti-HRP antibody and Sulfo-NHS-LC_Biotin (Pierce Co.), the molar ratio of 1: 2 becomes zero by Uni were mixed and reacted for 30 minutes at room temperature (20 to 30 ° C).
  • the reaction solution was passed through a 5 mL desalting column, and the target antibody fraction was recovered to obtain a biotinylated anti-HRP antibody.
  • Biotinylated anti-HRP antibody and 550mer oligonucleotide were mixed in a 1: 1 molar ratio.
  • NeutrAvidin Pierce
  • the reaction solution was passed through a 5 mL desalting column, and the target fraction was collected to obtain a solution of anti-HRP antibody (oligonucleotide-labeled antibody) labeled with a 550-mer oligonucleotide chain.
  • Amplification step (Amplification of oligonucleic acid strand)
  • an EcoRI enzyme solution was first prepared at the following volume ratio.
  • the liquid in each well was collected and centrifuged to obtain a supernatant (including the oligonucleotide fragment after EcoRI treatment).
  • Sterilized water appropriate amount (about 4.8 ⁇ L)
  • the detection method of the present invention was able to achieve a sensitivity improvement of about 134 times compared to the conventional ELISA method (see FIG. 3).
  • a novel method for detecting HCV is a simple and low-cost method that can easily detect even a trace amount of viruses and microorganisms that could not be detected in the past. You can power to provide.
  • a detection kit for carrying out the detection method can be provided.
  • the detection method of the present invention cannot be found by a known immunoassay method such as the HCV core protein quantification method! /, HCV-infected persons, that is, "the amount of HCV infection is extremely small and sufficient treatment is achieved by administration of interferon.
  • the present invention is extremely useful in the above points.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention est destinée à fournir un procédé qui est simple et peu coûteux et qui est capable de détecter facilement un virus ou un micro-organisme même à un faible niveau auquel la détection était impossible dans le passé. En particulier, un procédé qui est capable de détecter un HCV à un faible niveau auquel un effet thérapeutique de l'administration d'interleukine peut se révéler suffisant est obtenu. En outre, un kit de détection pour obtenir ces procédés est fourni. En particulier, le procédé de détection de l'invention est caractérisé en ce qu'il comprend les étapes consistant à : lier un virus et/ou un micro-organisme dans un échantillon d'essai à un anticorps primaire en phase solide ; lier un anticorps secondaire au virus et/ou micro-organisme lié à l'anticorps primaire ; lier une substance de liaison à l'anticorps secondaire marqué avec un brin d'acide oligonucléique à l'anticorps secondaire lié au virus et/ou micro-organisme ; amplifier le brin d'acide oligonucléique ; et détecter le produit amplifié.
PCT/JP2007/071410 2006-11-02 2007-11-02 Procédé efficace pour la détection d'antigène, de virus, de cellules et de micro-organismes Ceased WO2008053992A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-298825 2006-11-02
JP2006298825 2006-11-02

Publications (1)

Publication Number Publication Date
WO2008053992A1 true WO2008053992A1 (fr) 2008-05-08

Family

ID=39344331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/071410 Ceased WO2008053992A1 (fr) 2006-11-02 2007-11-02 Procédé efficace pour la détection d'antigène, de virus, de cellules et de micro-organismes

Country Status (1)

Country Link
WO (1) WO2008053992A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20111308U1 (de) * 2000-07-12 2001-12-20 Roboscreen Gesellschaft für molekulare Biotechnologie mbH, 04129 Leipzig Verschlussvorrichtung für Mehrfach-Reaktionsräume

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20111308U1 (de) * 2000-07-12 2001-12-20 Roboscreen Gesellschaft für molekulare Biotechnologie mbH, 04129 Leipzig Verschlussvorrichtung für Mehrfach-Reaktionsräume

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NIEMEYER C.M. ET AL.: "Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification", TRENDS IN BIOTECHNOL., vol. 23, 2005, pages 208 - 216, XP025290673, DOI: doi:10.1016/j.tibtech.2005.02.006 *
SHIBASAKI F. ET AL.: "S1-4 Kokando Doji Takomoku (MUSTag) Assay-ho: MUSTag Inside o Mezashite", THE JOURNAL OF CLINICAL SCIENCE, vol. 35, no. SUPPL. 2, September 2006 (2006-09-01), pages 16 *
ZHOU H. ET AL.: "Universal immuno-PCR for ultra-sensitive target protein detection", NUCLEIC ACIDS RES., vol. 21, 1993, pages 6038 - 6039, XP001146984 *

Similar Documents

Publication Publication Date Title
US20040110167A1 (en) Lateral flow system for nucleic acid detection
JP2015533282A (ja) Ｐｃｒ法に基いた生体物質を並列で検出するためのアッセイ
CN104928335A (zh) 用于扩增多个靶标的扩增子拯救多重聚合酶链式反应
JP2008518605A (ja) 同種の分析物検出
JPH11509100A (ja) 核酸抽出、増幅および検出を統合する自己充足装置
JP2004509648A (ja) 非病原性又は病原性インフルエンザａサブタイプｈ５ウイルス検出キット
AU3430001A (en) Methods and kits for proximity probing
EP1570090A4 (fr) Dispositif de stockage d'echantillons biologiques et procede permettant de deceler une eventuelle contamination d'echantillons biologiques
US20230332255A1 (en) Crispr-cas-based detection of sars-cov-2 using recombinase polymerase amplification
TW201002825A (en) Novel method and kit for diagnosis of mycobacterium tuberculosis and nontuberculous mycobacterium
US20180237868A1 (en) Method and kit for the field diagnosis of caprine arthritis-encephalitis virus (caev) infection
US9632078B2 (en) Detection of antigens
AU773046B2 (en) Test system for detecting different markers, and production and use thereof
WO1993003184A1 (fr) Procede et composition permettant de detecter la maladie de lyme
US6268123B1 (en) Direct and biochemically functional detection process of retrovirus in biological samples
WO2008053992A1 (fr) Procédé efficace pour la détection d'antigène, de virus, de cellules et de micro-organismes
EP3967772A1 (fr) Outils et procédés utiles pour la détection de l'intolérance au lactose et leurs utilisations
KR20180081445A (ko) 핵산의 신속 검출법 및 이를 이용한 질병의 신속 진단 방법
WO2008004706A1 (fr) Procédé de détection d'une substance cible à l'aide d'un procédé d'amplification de l'acide nucléique, disponible dans des conditions thermostatiques
CN110741099B (zh) 评估个体的登革热病毒感染严重程度的方法、检测装置及检测试剂盒
TWI624668B (zh) 評估個體之登革熱病毒感染嚴重程度的方法
KR100785418B1 (ko) Ｂ형 간염바이러스, ｃ형 간염 바이러스,인간면역결핍바이러스의 동시진단 분석방법
JP2021019539A (ja) 核酸検出方法及びキット
KR100723574B1 (ko) 신규 프로브를 이용하여 돼지콜레라 바이러스 유전자를정량분석하는 방법 및 이의 시약
Mostafa et al. Current Trends of SARS-CoV-2 and its New Variants Diagnostics in Different Body Fluids: Surface Antigen, Antibody, Nucleic Acid, and RNA Sequencing Detection Techniques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07831144

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07831144

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP